{
    "clinical_study": {
        "@rank": "74084", 
        "brief_summary": {
            "textblock": "PRIMARY: To evaluate the clinical activity of foscarnet cream on the index lesion of\n      mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients previously\n      unresponsive to acyclovir treatment.\n\n      SECONDARY: To evaluate the clinical activity and virologic activity of foscarnet cream on\n      all treated lesions in this patient population. To evaluate the local tolerance and side\n      effects of treatment with foscarnet cream in this patient population."
        }, 
        "brief_title": "The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment", 
        "condition": [
            "Herpes Simplex", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Herpes Simplex", 
                "Virus Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive topical applications of one percent foscarnet cream five times daily for up\n      to 6 weeks; those who show no evidence of epithelialization of the index lesion after 3 or\n      more weeks are removed from study and offered intravenous foscarnet. Patients who show a\n      good response to topical foscarnet cream at the end of 6 weeks may continue receiving\n      treatment at the discretion of the investigator."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Ganciclovir (provided drug was administered for at least 14 days prior to study\n             entry, and the HSV isolate exhibits resistance against acyclovir).\n\n          -  Other medication considered necessary for patient's welfare, at the discretion of the\n             investigator.\n\n        Patients must have:\n\n          -  HIV infection or AIDS.\n\n          -  Mucocutaneous HSV infection with at least one clinically evaluable lesion.\n\n          -  Prior acyclovir without clinical benefit.\n\n          -  Life expectancy of at least 3 months.\n\n          -  Consent of parent or guardian if less than 18 years of age.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Known hypersensitivity to the study drug.\n\n          -  Any medical, psychiatric, or other condition that would preclude study compliance.\n\n          -  Incapable of self administration of medication or presence of a care provider\n             administering medication.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Intravenous foscarnet for current episode of HSV.\n\n          -  Acyclovir, interferon, or any investigational drug that might have anti-HSV activity\n             (e.g., 256U87, HPMPC, BVDaraU, trifluridine).\n\n        Patients with the following prior condition are excluded:\n\n        Previous participation in the study.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Intravenous foscarnet within 2 months prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "12", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002144", 
            "org_study_id": "240A", 
            "secondary_id": "92-FT-57"
        }, 
        "intervention": {
            "intervention_name": "Foscarnet sodium", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Acyclovir", 
                "Foscarnet", 
                "Phosphonoacetic Acid"
            ]
        }, 
        "keyword": [
            "Herpes Simplex", 
            "Foscarnet", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "CARE Ctr / UCLA Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20037"
                    }, 
                    "name": "George Washington Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "South Miami Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60610"
                    }, 
                    "name": "Dr Thomas Klein"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "Bellevue Hosp Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Univ Hosps of Cleveland"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02908"
                    }, 
                    "name": "Roger Williams Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Milwaukee County Med Complex"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment", 
        "overall_official": {
            "last_name": "Hardy WD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Hardy D, Javaly K, Wohlfeiler M, Kalayjian R, Klein T, Bryson Y, Graford K, Martin-Munley S. Phase I, pilot study of the safety and efficacy of foscarnet (PFA) cream for treatment (Rx) of acyclovir-unresponsive (ACV-R) herpes simplex (HSV). Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:83"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002144"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astra USA", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1996"
    }, 
    "geocoordinates": {
        "Bellevue Hosp Ctr": "40.714 -74.006", 
        "CARE Ctr / UCLA Med Ctr": "34.052 -118.244", 
        "Dr Thomas Klein": "41.878 -87.63", 
        "George Washington Univ Med Ctr": "38.895 -77.036", 
        "Milwaukee County Med Complex": "43.039 -87.906", 
        "Roger Williams Med Ctr": "41.824 -71.413", 
        "South Miami Hosp": "25.789 -80.226", 
        "Univ Hosps of Cleveland": "41.499 -81.695"
    }
}